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ABSTRACT
Aims/Introduction: The glucose-lowering effects of the glucagon-like peptide-
1 receptor agonist, liraglutide, have been shown to rely on remaining b-cell function. How-
ever, the possible associations of remaining b-cell function with the glucose-lowering effects
of liraglutide in combination with basal insulin remain unknown and warrant investigation.
Materials and Methods: This was a single-center, retrospective, observational study car-
ried out in a private hospital in Osaka, Japan. Type 2 diabetes patients who received a prescrip-
tion change from insulin therapy, both multiple-dose insulin and basal insulin-supported oral
therapy, to liraglutide and basal insulin combination and continued the therapy for 54 weeks
without additional oral antidiabetic drugs or bolus insulin were retrospectively analyzed.
Results: Among the 72 participants who received a prescription change frommultiple-
dose insulin and basal insulin-supported oral therapy to liraglutide and basal insulin combina-
tion, 57 continued the therapy for 54 weeks. Of those who continued the therapy without
receiving additional oral antidiabetic drugs or bolus insulin, seven participants achieved gly-
cated hemoglobin < 7.0% at 54 weeks, but 30 participants did not. The participants who
achieved glycated hemoglobin < 7.0% at 54 weeks had a significantly higher C-peptide
immunoreactivity index, a b-cell function-related index frequently used in Japanese clinical
settings. The receiver operating curve analysis showed that the C-peptide immunoreactivity
index cut-off value for the achievement of glycated hemoglobin <7.0% at 54 weeks is 1.103.
Conclusions: The current findings show that the glucose-lowering effects of liraglutide
rely on remaining b-cell function, even when used with basal insulin; and suggest that
liraglutide and basal insulin combination might require additional bolus insulin to fully
compensate insulin insufficiency in individuals with reduced b-cell function.
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INTRODUCTION
Type 2 diabetes is characterized by a progressive decline in
b-cell function and increased insulin resistance that contribute
to chronic hyperglycemia and subsequent diabetic complica-
tions1. Therefore, antidiabetes strategies so far have mainly
focused on improving b-cell function and insulin resistance.
Among them, glucagon-like petide-1 receptor (GLP-1R) ago-
nists, especially the so-called long-acting GLP-1R agonists, such
as liraglutide, have been gaining attention because they enhance
insulin secretion glucose-dependently and concurrently amelio-
rate insulin resistance through bodyweight reduction2,3. Previ-
ous studies showed that the glucose-lowering effects of the
long-acting GLP-1R agonist, liraglutide, rely on remaining b-cell
function, as evaluated by postprandial levels of C-peptide
immunoreactivity (CPR) 4, the fasting C-peptide index (CPI) or
the CPR/plasma glucose ratio5–8 and glucagon-stimulated
increments of CPR7. These ﬁndings suggest that the earlier
initiation of long-acting GLP-1R agonists results in greater
glucose-lowering effects in patients with type 2 diabetes. A
meta-analysis of clinical trials on GLP-1R agonists and basal
insulin combination therapy showed that they improve gly-
cated hemoglobin (HbA1c) similarly to basal–bolus insulin
therapy with a reduced risk of hypoglycemia and bodyweight
gain9. Therefore, it is conceivable that long-acting GLP-1R
agonists are effective in type 2 diabetes patients with reduced
remaining b-cell function when used with basal insulin. How-
ever, this has not been tested in clinical trials or in clinical
settings, and requires further investigation. The current retro-
spective study was designed to evaluate: (i) the HbA1c-lower-
ing effects of liraglutide and basal insulin combination
therapy in type 2 diabetes patients who had previously
received insulin therapy, both multiple-dose insulin (MDI)
and basal insulin-supported oral therapy (BOT); and (ii) the
possible association of remaining b-cell function with the
HbA1c-lowering effects of the therapy.
METHODS
Participants
A total of 72 type 2 diabetes patients who received a prescrip-
tion change from insulin therapy, MDI or BOT to liraglutide
and basal insulin combination therapy at Kansai Electric Power
Hospital (Osaka, Japan) between September 2014 and February
2016 were retrospectively analyzed. Patients with type 1 dia-
betes, pregnancy, pancreatic disease, liver disease, renal disease,
malignancy or receiving diabetogenic medication were excluded.
Patients with severe renal failure (creatinine clearance
rate < 30 mL/min) and/or those undergoing dialysis were also
excluded, as serum CPR levels are modiﬁed in these conditions.
Physical and laboratory data including HbA1c were acquired
before and 12 – 3, 24 – 3, 36 – 3 and 54 – 3 weeks after the
initiation of liraglutide and basal insulin combination therapy.
A schematic diagram of the study participants is summarized
in Figure 1. Of the 72 patients, 15 discontinued liraglutide as a
result of hyperglycemia (1 patient), gastrointestinal side-effects
(4 patients) and other reasons (10 patients); 12 patients contin-
ued liraglutide therapy while receiving additional oral antidia-
betic drugs (OAD) or insulin during 54 weeks, and the
remaining 45 patients continued liraglutide therapy without
additional OADs or bolus insulin. There were 37 patients
whose HbA1c values at week 54 were available. No hypo-
glycemia requiring hospitalization occurred during the study
period.
Measurements
HbA1c was measured using high-performance liquid chro-
matography with cation-exchange resins that separate the stable
form of b-N1-mono-deoxyfructosyl Hb. The results are shown
as National Glycohemoglobin Standardization Program values
as recommended by the Japan Diabetes Society10. The CPI,
which is closely correlated with other indices of b-cell function,
such as homeostatic model assessment of b-cell function and
insulinogenic index11–13, and has been widely used as a practi-
cal index to estimate b-cell function in clinical settings14, was
calculated as follows: 100 9 fasting CPR / fasting plasma glu-
cose. The patients continued pre-existing insulin therapy up
until the night before the measurement of fasting serum CPR
in the morning to avoid hyperglycemia. CPR was measured
using Lumipulse Presto C-peptide (Fujirebio Inc., Tokyo,
Japan). Other laboratory measurements including plasma glu-
cose were measured by standard assays.
Statistical analysis
The patient characteristics and results are reported as the
mean – standard error of the mean (SEM). The statistical anal-
ysis was carried out using SPSS Statistics 22 software (IBM
Corp., Armonk, NY, USA). Repeated measures were analyzed
using a mixed-effects model. Clinical parameters were com-
pared between the two groups at single time-points using the
Mann–Whitney U-test. P-values < 0.05 were considered statisti-
cally signiﬁcant. Receiver operating characteristic curves were
constructed for the CPI. The sensitivity, speciﬁcity, cut-off point
and area under the receiver operating characteristic curve were
also calculated.
RESULTS
Of the 57 patients who initiated and continued liraglutide
and basal insulin combination therapy for 54 weeks, we ana-
lyzed 37 patients who did not take additional OADs or
bolus insulin (Figure 1). After the initiation of liraglutide and
basal insulin combination therapy, HbA1c slightly improved
(baseline 8.5 – 0.3% and at 54 weeks 8.0 – 0.2%; P = 0.138),
with signiﬁcant reductions in bodyweight (baseline 73.3 –
2.8 kg and at 54 weeks 68.6 – 2.4 kg; P < 0.01), insulin dose
(baseline 25.9 – 3.1 units/day and at 54 weeks 16.2 –
1.4 units/day; P < 0.01) and insulin dose per bodyweight
(baseline 0.34 – 0.04 units/kg bodyweight/day and at 54 weeks
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0.23 – 0.02 units/kg bodyweight/day; P < 0.01; Figure 2a–d,
black lines).
We then addressed whether remaining b-cell function affects
the achievement of HbA1c < 7.0% at 54 weeks after the initia-
tion of liraglutide and basal insulin combination therapy.
Among the 37 patients, the patients who achieved
HbA1c < 7.0% showed higher HbA1c values and bodyweight
throughout the observation period, although it did not reach
statistical signiﬁcance. These patients had a total insulin dose
similar to patients who did not achieve HbA1c < 7.0%. Impor-
tantly, the baseline values of the b-cell function index, CPI,
were signiﬁcantly higher in patients who achieved
HbA1c < 7.0% than in those who did not achieve
HbA1c < 7.0% (1.50 – 0.22 vs 0.98 – 0.10; P = 0.04; Fig-
ure 2e). The receiver operating characteristic analysis showed
that the cut-off CPI value for the achievement of
HbA1c < 7.0% was 1.103 ng/mL (area under the curve 0.752;
95% conﬁdence interval 0.548–0.957; sensitivity 86% and speci-
ﬁcity 67%; Figure 2f).
We also carried out a subgroup analysis that showed that
the changes in HbA1c from baseline to 54 weeks were affected
only by baseline HbA1c, and did not differ by the baseline val-
ues of age, body mass index (BMI) and type 2 diabetes duration,
the insulin dose or the type of pre-existing insulin therapy (MDI
vs BOT; Figure 3). Although the changes in bodyweight and
insulin dose were signiﬁcantly affected by baseline BMI, insulin
dose and insulin therapy type, the bodyweight and insulin dose
at 54 weeks were not affected by baseline insulin therapy type
(Figure 3). Importantly, the dose of liraglutide did not differ by
the baseline age (≥65 years, 0.86 – 0.03 mg and <65 years,
0.81 – 0.03 mg; P = 0.421), the medians of baseline HbA1c
(≥8.2%, 0.82 – 0.03 mg and <8.2%, 0.85 – 0.03 mg; P = 0.538),
baseline BMI (≥26.36 kg/m2, 0.87 – 0.02 mg and <26.36 kg/m2,
0.81 – 0.03 mg; P = 0.298), type 2 diabetes duration (≥16 years,
0.82 – 0.03 mg and <16 years, 0.85 – 0.03 mg; P = 0.620),
baseline insulin dose (≥0.4 units/kg bodyweight/day,
0.85 – 0.03 mg and <0.4 units/kg bodyweight/day,
0.82 – 0.03 mg; P = 0.538) or the type of pre-existing insulin
therapy (MDI 0.85 – 0.02 mg and BOT 0.79 – 0.05 mg;
P = 0.332). The ratio of basal insulin and liraglutide (units of
basal insulin per mg of liraglutide) did not differ by baseline age
(≥65 years, 20.74 – 2.47 and <65 years, 18.13 – 2.34;
P = 0.354), the medians of baseline HbA1c (≥8.2%, 21.93 – 2.75
and <8.2%, 17.16 – 1.92; P = 0.159), type 2 diabetes duration
(≥16 years, 21.88 – 2.28 and <16 years, 17.22 – 2.53;
P = 0.258) or the type of pre-existing insulin therapy (MDI
21.24 – 2.06 and BOT, 15.76 – 2.92; P = 0.204), but it differed
by the medians of baseline BMI (≥26.36 kg/m2, 23.22 – 2.70 and
<26.36 kg/m2, 15.80 – 1.75; P = 0.020) and the medians of base-
line daily insulin dose per bodyweight (≥0.4 units/kg body-
weight/day, 23.98 – 2.22 and <0.4 units/kg bodyweight/day,
15.00 – 2.21; P = 0.014).
DISCUSSION
The current study showed that the achievement of
HbA1c < 7.0% by liraglutide and basal insulin combination
therapy was affected by remaining b-cell function, and that the
cut-off value of the b-cell function index, CPI, for this target
was 1.103, suggesting that the therapy requires additional OAD
or bolus insulin in patients with CPI < 1.103 to achieve
HbA1c < 7.0% 1 year after initiation. The present study also
suggested that liraglutide and basal insulin combination therapy
All subjects who were changed to basal insulin
plus liraglutide: n = 72
Subjects who received no additional OAD(s) or
insulin during weeks 0-54: n = 37
Subjects with HbA1c ≥7.0% at 54 weeks: n = 30Subjects with HbA1c <7.0% at 54 weeks: n = 7
Subjects who continued liraglutide 
during weeks 0-54: n = 57
Subjects who discontinued liraglutide during
weeks 0-54 due to AE: nausea n = 4, others n = 10
Subjects whose HbA1c at 54 weeks was not
available: n = 8
Subjects who received additional OAD(s) or
bolus insulin during weeks 0-54: n = 12 
Subjects who discontinued liraglutide 
during weeks 0-54 due to hyperglycemia n = 1
Figure 1 | Schematic diagram of the study participants. HbA1c, glycated hemoglobin; OAD, oral antidiabetic drug.
824 J Diabetes Investig Vol. 9 No. 4 July 2018 ª 2017 The Authors. Journal of Diabetes Investigation published by AASD and John Wiley & Sons Australia, Ltd
O R I G I N A L A R T I C L E
Usui et al. http://onlinelibrary.wiley.com/journal/jdi
improves HbA1c and bodyweight regardless of baseline charac-
teristics, such as age, BMI, type 2 diabetes duration, insulin
therapy type and the insulin dose.
Liraglutide exerts glucose-lowering effects by enhancing basal
and postprandial insulin secretion from pancreatic b-cells2,15.
Therefore, it is conceivable that remaining b-cell function is
one of the critical determinants in the glucose-lowering effects
of liraglutide. Our groups and others previously reported that
liraglutide exerts greater HbA1c-lowering effects among non-
insulin-treated type 2 diabetes patients with ample b-cell func-
tion5,7,16. However, whether these HbA1c-lowering effects
depend on remaining b-cell function in patients receiving basal
insulin is unknown. As clearly shown in the current study, the
HbA1c-lowering effects depend on remaining b-cell func-
tion, even in patients receiving liraglutide with basal insulin.
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Figure 2 | Changes during the 54-week period in (a) glycated hemoglobin (HbA1c), (b) bodyweight, (c) insulin dose and (d) insulin dose per
bodyweight. Black, all participants (n = 37); blue, patients with HbA1c < 7% at 54 weeks (n = 7); red, patients with HbA1c ≥ 7.0% at 54 weeks
(n = 30). Each value represents the mean – standard error of the mean. Time-course curves were analyzed by mixed-effects models including
group, time, and the interaction of group and time, and the P-values are shown. *P < 0.05 (vs 0 week) in all participants and #P < 0.05 (vs
patients with HbA1c < 7.0% at 54 weeks) by the Mann–Whitney U-test. (e) Comparison of C-peptide index (CPI) in patients with HbA1c < 7.0%
and those with HbA1c ≥ 7.0% at 54 weeks. Black bar, all participants (n = 37); blue bar, patients with HbA1c < 7.0% at 54 weeks (n = 7); red bar,
patients with HbA1c ≥ 7.0% at 54 weeks (n = 30). Each value represents the mean – standard error of the mean. *P < 0.05 by the Mann–Whitney
U-test. (f) Receiver operating characteristic (ROC) curves of CPI to predict the achievement of HbA1c < 7.0% at 54 weeks without adding additional
antidiabetic drugs or bolus insulin. The area under the curve (AUC) is 0.752 (95% confidence interval 0.548–0.957). The estimated cut-off point is
1.103 with 86% sensitivity and 67% specificity.
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HbA1c < 7.0% by liraglutide and basal insulin combination
therapy (i.e., 1.103) is lower than that of liraglutide – sulfony-
lurea therapy (i.e., 1.86) 7, suggesting that basal insulin can
compensate for the b-cell function required for liraglutide to
enhance basal insulin secretion. However, as suggested by the
current study, liraglutide and basal insulin combination therapy
might require additional bolus insulin to fully compensate insu-
lin insufﬁciency in individuals with reduced b-cell function.
Therefore, it would be interesting to evaluate the b-cell function
requirement for the achievement of HbA1c < 7.0% in individu-
als receiving both basal and bolus insulin. More than 70% of
the 37 patients examined in the current study stopped receiving
pre-existing OADs and/or bolus insulin, and no washout peri-
ods were implemented before the initiation of the basal insulin
and liraglutide combination therapy, making it difﬁcult to eval-
uate patients’ responses based on changes in HbA1c from base-
line to 54 weeks. In addition to the achievement of
HbA1c < 7.0% at 54 weeks, we also evaluated CPI in HbA1c
tertiles at 54 weeks, and found that the lowest HbA1c tertile
had the highest CPI (Figure S2).
Insulin therapy, especially MDI, has been the most powerful
tool for glycemic control, but the risk of hypoglycemia and
increased bodyweight have been problems in the management of
type 2 diabetes. GLP-1R agonist and basal insulin combination
therapy has been gaining attention, because it carries lower risks
for hypoglycemia and bodyweight gain, and improves quality of
life because of less frequent injections and exerts HbA1c-lower-
ing effects similarly to MDI according to randomized controlled
trials17. Consistent with the results of randomized controlled tri-
als, liraglutide and basal insulin combination therapy improved
HbA1c, and decreased bodyweight and the insulin dose when
switched from MDI or BOT in the current study (Figure 2) and
in recent clinical trials in Japanese type 2 diabetes patients18,19.
Liraglutide and basal insulin combination therapy is effective
regardless of baseline age, BMI, disease duration, insulin dose
and the type of insulin injections (Figure 3). In addition, the
ratio of basal insulin and liraglutide was not affected by baseline
values of age, HbA1c, type 2 diabetes duration or the type of
pre-existing insulin therapy, suggesting a broad indication for a
ﬁxed-ratio combination of liraglutide and basal insulin in Japa-
nese type 2 diabetes patients similar to type 2 diabetes patients
of other ethnicities20,21. The ratio of basal insulin and liraglutide
signiﬁcantly differ between individuals with baseline
BMI ≥ 26.36 kg/m2 and those < 26.36 kg/m2; and between
individuals with baseline insulin dose ≥ 0.4 unit/kg/day and
those with < 0.4 unit/kg/day, suggesting that the ratio should be
determined in light of obesity and subsequent insulin resistance.
However, it is important to note that liraglutide up to 0.9 mg
q.d., unlike up to 1.8 mg q.d. in other countries, is currently
approved in Japan and that the results need to be interpreted
accordingly.
There were several limitations to the current study. First, the
sample size of the current study was limited, as liraglutide and
basal insulin combination therapy had only been approved in
Japan for <3 years. Second, just 19% of the patients achieved
HbA1c < 7.0% at 54 weeks, partly due to the new guideline of
HbA1c targets for the elderly announced by the Japan Diabetes
Society in May 2016 (e.g., HbA1c 6.5–7.5% for individuals aged
≥65-years and individuals aged<75 years with normal cognitive
function and activities of daily living, and with the use of insu-
lin, sulfonylurea and glinide) 22. Third, because of the retrospec-
tive nature of the study, there is no pre-ﬁxed rule for dose
adjustments of basal insulin by the physician-in-charge. There-
fore, it is difﬁcult to exclude the possibility that dose adjust-
ments of basal insulin affected the overall results, including the
CPI cut-off value, although the basal insulin dose did not differ
regardless of HbA1c < 7.0% achievement (Figure 2c,d). In addi-
tion, there is no pre-ﬁxed rule for prescription changes. The
inclusion of the 12 patients originally excluded as a result of
additional OADs or bolus insulin showed that baseline CPI was
higher in the group achieving HbA1c < 7.0%, although it did
not reach statistical signiﬁcance (Figure S1). Five out of the 12
excluded patients had baseline CPI values (1.71 – 0.13) that
were higher than the mean CPI value of the group achieving
HbA1c < 7.0% (Table 1). These ﬁve patients had higher base-
line insulin dose per bodyweight (0.47 – 0.08 units/kg body-
weight/day) and younger baseline age (52.2 – 1.6 years), despite
a similar baseline HbA1c (8.1 – 0.4%) compared with the group
achieving HbA1c < 7.0% (Table 1), suggesting that additional
factors (e.g., overeating and insulin resistance) might also con-
tribute to achievement of HbA1c < 7.0% by liraglutide and
basal insulin combination therapy. Fourth, linear associations of
CPI with b-cell function at higher fasting glucose ranges were
not investigated. However, fasting glucose levels in the current
study participants were similar to or lower than those described
in previous studies evaluating remaining b-cell function to avoid
insulin injections and those investigating associations of CPI
with other indices of b-cell function12,13,23. Despite these limita-
tions, the current ﬁndings strongly suggest that liraglutide
requires some remaining b-cell function to exert glucose-lower-
ing effects, even when used with basal insulin, and suggest that
liraglutide and basal insulin therapy requires additional OAD or
bolus insulin to achieve ideal HbA1c target.
In conclusion, the current study found that the patients who
achieved HbA1c < 7.0% by liraglutide and basal insulin combi-
nation therapy had more remaining b-cell function, and sug-
gests that the earlier introduction of liraglutide allows better
glycemic control outcomes, even when used with basal insulin.
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Table 1 | Baseline characteristics of the patients who received a prescription change from insulin therapy to liraglutide and basal insulin
combination therapy
All patients Patients who
achieved HbA1c
< 7.0% at 54 weeks
Patients who did
not achieve HbA1c
< 7.0% at 54 weeks
P-value
n (%male) 37 (59.5%) 7 (71.4%) 30 (56.7%)
Age at baseline (years) 63.0 – 2.0 61.3 – 5.1 63.4 – 2.2 0.955
Estimated duration of type 2 diabetes at baseline (years) 15.5 – 1.5 10.1 – 3.8 16.8 – 1.6 0.084
BMI at baseline (kg/m2) 27.9 – 0.7 30.2 – 2.1 27.4 – 0.8 0.160
HbA1c at baseline (%) 8.5 – 0.3 7.8 – 0.5 8.6 – 0.3 0.138
HbA1c at 54 weeks (%) 8.0 – 0.2 6.3 – 0.2 8.4 – 0.2 <0.001
Patients with HbA1c < 7% at baseline (%) 5.4 14.3 3.3
Fasting plasma glucose at baseline (mg/dL) 120.9 – 5.6 119.9 – 7.3 121.2 – 6.7 0.776
Fasting C-peptide at baseline (ng/mL) 1.37 – 0.15 1.79 – 0.28 1.27 – 0.18 0.077
CPI at baseline 1.08 – 0.09 1.50 – 0.22 0.98 – 0.09 0.040
Insulin injection type before liraglutide initiation, MDI/BOT (%) 70/30 57/43 73/27
Patients on OAD at baseline (%)
Metformin 46 57 43
DPP-4 inhibitors 49 43 50
Sulfonylureas 11 0 13
SGLT2 inhibitors 3 0 3
Glinides 3 0 3
a-Glucosidase inhibitors 3 0 3
Thiazolidinedione 0 0 0
Insulin dose before liraglutide initiation (unit/kg bodyweight/day) 0.34 – 0.04 0.34 – 0.11 0.34 – 0.04 0.458
Insulin dose before liraglutide initiation (units/day) 25.9 – 3.1 26.0 – 7.1 25.9 – 3.5 0.955
Insulin dose at 54 weeks (units/kg bodyweight/day) 0.23 – 0.20 0.20 – 0.08 0.23 – 0.18 0.391
Insulin dose at 54 weeks (units/day) 16.2 – 1.4 14.9 – 5.4 16.5 – 1.3 0.556
Liraglutide dose at 54 weeks (mg/day) 0.84 – 0.02 0.81 – 0.06 0.84 – 0.02 0.747
A ratio of basal insulin to liraglutide at 54 weeks (units/mg) 19.61 – 1.72 17.78 – 6.20 20.04 – 1.63 0.531
Each value represents the mean – standard error of the mean. CPI, 100 9 (fasting serum C-peptide [ng/mL]) / (fasting plasma glucose [mg/dL]).
P-values were calculated by the Mann–Whitney U-test for patients who achieved glycated hemoglobin (HbA1c) < 7.0% at 54 weeks vs patients
who did not achieve HbA1c < 7.0% at 54 weeks. BMI, body mass index; BOT, basal insulin-supported oral therapy; CPI, C-peptide index; DPP-4,
dipeptidyl peptidase-4; MDI, multiple-dose insulin; OAD, oral antidiabetic drugs; SGLT2, sodium-glucose cotransporter 2.
Figure 3 | Subgroup analysis of glycated hemoglobin (HbA1c) and bodyweight changes by baseline HbA1c, body mass index (BMI), estimated
duration of type 2 diabetes, insulin dose per bodyweight and insulin injection types. The patients who continued liraglutide and basal insulin
combination therapy for 54 weeks without taking additional anti-oral diabetic drugs or bolus insulin were stratified by age (<65 or ≥65 years), baseline
HbA1c (median 8.2%), baseline BMI (median 26.36 kg/m2), estimated duration of diabetes (median 16.0 years), total insulin dose (median 0.4 units/kg
bodyweight/day) and insulin injection types (multiple dose insulin [MDI] or basal insulin-supported oral therapy [BOT]). Blue, patients with aged
<65 years (n = 16) or below the medians (HbA1c, n = 18; BMI, n = 18; duration of type 2 diabetes, n = 18; and total insulin doses, n = 18) or those
with BOT (n = 11); red, patients aged ≥65 years (n = 21) or above the medians (HbA1c, n = 19; BMI, n = 19; duration of type 2 diabetes, n = 19; and
total insulin doses, n = 19) or those with MDI (n = 26). Each value represents the mean – standard error of the mean. Time-course curves were
analyzed by mixed-effects models including group, time and the interaction of group and time, and the P-values are shown. #P < 0.05 (vs patients
with values below the medians or patients with BOT) by the Mann–Whitney U-test.
828 J Diabetes Investig Vol. 9 No. 4 July 2018 ª 2017 The Authors. Journal of Diabetes Investigation published by AASD and John Wiley & Sons Australia, Ltd
O R I G I N A L A R T I C L E
Usui et al. http://onlinelibrary.wiley.com/journal/jdi
also received clinically commissioned/joint research grants from
the Japan Vascular Disease Research Foundation. Yutaka Seino
received consulting or speaker fees from Eli Lilly Japan K.K.,
Sanoﬁ K.K., Novo Nordisk Pharma Inc., Glaxo-Smith-Kline,
Taisho Pharmaceutical Co., Ltd., Taisho Toyama Pharmaceuti-
cal Co., Ltd., Astellas Pharma Inc., BD, Nippon Boehringer
Ingelheim Co., Ltd., Johnson & Johnson and Takeda Pharma-
ceutical Company Limited. Yutaka Seino also received clinically
commissioned/joint research grants from Nippon Boehringer
Ingelheim Co., Ltd., Eli Lilly and Company, Taisho Toyama
Pharmaceutical Co. Ltd., MSD K.K., Ono Pharmaceutical Co.
Ltd., Novo Nordisk Pharma Ltd., and Arklay Co. Ltd. Ryota
Usui, Yui Sakuramachi, Hitoshi Kuwata, Hisato Tatsuoka,
Kenta Murotani and Yusuke Seino declare no conﬂict of inter-
est.
REFERENCES
1. U.K. prospective diabetes study 16. Overview of 6 years’
therapy of type II diabetes: a progressive disease. U.K.
Prospective Diabetes Study Group. Diabetes 1995; 44: 1249–
1258.
2. Yabe D, Seino Y. Defining the role of GLP-1 receptor
agonists for individualized treatment of type 2 diabetes.
Expert Rev Endocrinol Metab 2014; 9: 659–670.
3. Meier JJ. GLP-1 receptor agonists for individualized
treatment of type 2 diabetes mellitus. Nat Rev Endocrinol
2012; 8: 728–742.
4. Iwao T, Sakai K, Sata M. Postprandial serum C-peptide is a
useful parameter in the prediction of successful switching
to liraglutide monotherapy from complex insulin therapy in
Japanese patients with type 2 diabetes. J Diabetes
Complications 2013; 27: 87–91.
5. Kozawa J, Inoue K, Iwamoto R, et al. Liraglutide is effective
in type 2 diabetic patients with sustained endogenous
insulin-secreting capacity. J Diabetes Investig 2012; 3: 294–
297.
6. Usui R, Yabe D, Kuwata H, et al. Retrospective analysis of
safety and efficacy of insulin-to-liraglutide switch in
Japanese type 2 diabetes: a caution against inappropriate
use in patients with reduced beta-cell function. J Diabetes
Investig. 2013; 4: 585–594.
7. Usui R, Yabe D, Kuwata H, et al. Retrospective
analysis of safety and efficacy of liraglutide
monotherapy and sulfonylurea-combination therapy
in Japanese type 2 diabetes: association of remaining
beta-cell function and achievement of HbA1c target
one year after initiation. J Diabetes Complications
2015; 29: 1203–1210.
8. Meier JJ, Vilsbøll T, Donsmark M, et al. Greater glycaemic
control is achieved with the once-daily human GLP-1
analogue liraglutide vs comparators across the continuum
of estimated beta cell mass. Diabetologia 2011; 1: S322.
9. Eng C, Kramer CK, Zinman B, et al. Glucagon-like peptide-1
receptor agonist and basal insulin combination treatment
for the management of type 2 diabetes: a systematic
review and meta-analysis. Lancet 2014; 384: 2228–2234.
10. Kashiwagi A, Kasuga M, Araki E, et al. International clinical
harmonization of glycated hemoglobin in Japan: from
Japan Diabetes Society to National Glycohemoglobin
Standardization Program values. J Diabet Investig 2012; 3:
39–40.
11. Okuno Y, Komada H, Sakaguchi K, et al. Postprandial serum
C-peptide to plasma glucose concentration ratio correlates
with oral glucose tolerance test- and glucose clamp-based
disposition indexes. Metabolism 2013; 62: 1470–1476.
12. Okuno Y, Sakaguchi K, Komada H, et al. Correlation of
serum CPR to plasma glucose ratio with various indices of
insulin secretion and diseases duration in type 2 diabetes.
Kobe J Med Sci 2013; 59: E44–E53.
13. Iwata M, Matsushita Y, Fukuda K, et al. Secretory units of
islets in transplantation index is a useful predictor of insulin
requirement in Japanese type 2 diabetic patients. J Diabetes
Investig 2014; 5: 570–580.
14. Saisho Y. Postprandial C-peptide to glucose ratio as a marker
of beta cell function: implication for the management of
Type 2 diabetes. Int J Mol Sci 2016; 17: 744.
15. Yabe D, Eto T, Shiramoto M, et al. Effects of DPP-4 inhibitor
linagliptin and GLP-1 receptor agonist liraglutide on
physiological response to hypoglycaemia in Japanese
subjects with type 2 diabetes: a randomized, open-label, 2-
arm parallel comparative, exploratory trial. Diabetes Obes
Metab 2017; 19: 442–447.
16. Kondo Y, Satoh S, Nagakura J, et al. Defining criteria for the
introduction of liraglutide using the glucagon stimulation
test in patients with type 2 diabetes. J Diabetes Investig
2013; 4: 571–575.
17. Maiorino MI, Chiodini P, Bellastella G, et al. Insulin and
glucagon-like peptide 1 receptor agonist combination
therapy in Type 2 diabetes: a systematic review and meta-
analysis of randomized controlled trials. Diabetes Care 2017;
40: 614–624.
18. Seino Y, Kaneko S, Fukuda S, et al. Combination therapy
with liraglutide and insulin in Japanese patients with type 2
diabetes: a 36-week, randomized, double-blind, parallel-
group trial. J Diabetes Investig. 2016; 7: 565–573.
19. Seino Y, Min KW, Niemoeller E, et al. Investigators EG-LAS.
randomized, double-blind, placebo-controlled trial of the
once-daily GLP-1 receptor agonist lixisenatide in Asian
patients with type 2 diabetes insufficiently controlled on
basal insulin with or without a sulfonylurea (GetGoal-L-Asia).
Diabetes Obes Metab 2012; 14: 910–917.
20. Gough SC, Bode BW, Woo VC, et al. One-year efficacy and
safety of a fixed combination of insulin degludec and
liraglutide in patients with type 2 diabetes: results of a 26-
week extension to a 26-week main trial. Diabetes Obes
Metab 2015; 17: 965–973.
21. Gough SC, Bode B, Woo V, et al. Efficacy and safety of a
fixed-ratio combination of insulin degludec and liraglutide
ª 2017 The Authors. Journal of Diabetes Investigation published by AASD and John Wiley & Sons Australia, Ltd J Diabetes Investig Vol. 9 No. 4 July 2018 829
O R I G I N A L A R T I C L E
http://onlinelibrary.wiley.com/journal/jdi Liraglutide and b-cell function
(IDegLira) compared with its components given alone:
results of a phase 3, open-label, randomised, 26-week, treat-
to-target trial in insulin-naive patients with type 2 diabetes.
Lancet Diabetes Endocrinol 2014; 2: 885–893.
22. Report Committee. Glycemic targets for elderly patients
with diabetes: Japan Diabetes Society (JDS)/Japan Geriatrics
Society (JGS) Joint Committee on Improving Care for
Elderly Patients with Diabetes. J Diabetes Investig. 2017; 8:
126–128.
23. Funakoshi S, Fujimoto S, Hamasaki A, et al. Utility of
indices using C-peptide levels for indication of insulin
therapy to achieve good glycemic control in Japanese
patientes with type 2 diaebtes. J Diabetes Investig 2011;
2: 297–303.
SUPPORTING INFORMATION
Additional Supporting Information may be found in the online version of this article:
Figure S1 | Comparison of C-peptide index (CPI) between patients with glycated hemoglobin <7.0% and those with glycated
hemoglobin ≥7.0% at 54 weeks in 49 patients, including 12 who were originally excluded due to receiving additional oral anti-dia-
betic drugs or bolus insulin.
Figure S2 | Comparison of C-peptide index (CPI) by glycated hemoglobin (HbA1c) at 54-week tertiles.
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